About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 1376 record(s)
Req # A-2022-001040
Adverse Drug Reactions (ADRs). Report numbers: E2B_05631885, E2B_05636120, E2B_05556948.Organization: Health Canada
January 2023
Req # A-2022-001041
Adverse Drug Reactions (ADRs). Report numbers: E2B_05653106, E2B_05632251, E2B_05635022, E2B_05653113, E2B_05643492.Organization: Health Canada
January 2023
Req # A-2022-001069
Adverse Drug Reactions (ADRs). Report numbers: 000994718, 001008281.Organization: Health Canada
January 2023
Req # A-2022-001082
Adverse Drug Reactions (ADRs) for CELEXA. Report numbers: E2B_04793638, E2B_04694880, E2B_03387893, E2B_04885161, 00975612, 00977234, 00978744, 00981330, E2B_05032996, 00978796.Organization: Health Canada
January 2023
Req # A-2022-001083
Adverse Drug Reactions (ADRs) for CIPRALEX. Report numbers: 00969860, 00969977, E2B_04775538, 00970817, 00974180, E2B_04988379, 00982282, 00980246.Organization: Health Canada
January 2023
Req # A-2022-001084
Adverse Drug Reactions (ADRs) for ARIPIPRAZOLE. Report numbers: E2B_05628287, E2B_05628312, E2B_05628332, E2B_05646859, E2B_05657705, E2B_05664355, E2B_05665043, E2B_05665088, E2B_05704273, E2B_05712679.Organization: Health Canada
January 2023
Req # A-2022-001085
Adverse Drug Reactions (ADRs) for ABILIFY. Report numbers: E2B_05661177, E2B_05661570, E2B_05662399, E2B_05664345, E2B_05664346, E2B_05664351, E2B_05664434, E2B_05664436, E2B_05664944, E2B_05644635.Organization: Health Canada
January 2023
Req # A-2022-001087
Adverse Drug Reactions (ADRs) for ABILIFY MAINTENA. Report numbers: E2B_05665045, E2B_05665144, E2B_05686891, E2B_05693250, E2B_05695992, E2B_05703028, E2B_05711493.Organization: Health Canada
January 2023
Req # A-2022-001129
Adverse Drug Reactions (ADRs). Report Number: 001010101.Organization: Health Canada
January 2023
Req # A-2022-001210
Adverse Drug Reaction (ADR). Report number: 000992869.Organization: Health Canada
January 2023